2025 United Kingdom Allergy Immunotherapy Revenue Opportunities Report
Description
The 2025 United Kingdom Allergy Immunotherapy Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Immunotherapy by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Allergy Immunotherapy in the United Kingdom are Stallergenes Greer, ALK-Abelló, Allergy Therapeutics, and GlaxoSmithKline (GSK). Stallergenes Greer, headquartered in London, UK, specializes in allergy immunotherapy and recently acquired Allergy Therapeutics to strengthen its market position. ALK-Abelló, a Denmark-based multinational, is known for its standardized SLIT tablets and SCIT formulations, including EMA-approved products for dust mite allergies. Allergy Therapeutics plc, based in Worthing, UK, focuses on diverse vaccine portfolios and rapid-onset immunotherapy innovations. GSK, a major UK pharmaceutical company, is also a key player in allergy therapeutics with a broad product portfolio targeting allergic disorders.
These companies dominate the UK allergy immunotherapy market, which was valued at approximately $603 million in 2022 and forecast to grow steadily with a CAGR of 4.4% through 2030. They focus on both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), with innovations in recombinant allergen platforms, improved formulations, and delivery methods enhancing treatment safety and efficacy. The market competitiveness is driven by regulatory approvals, product differentiation, and extensive clinical validation, ensuring these companies maintain leadership in allergy immunotherapy within the UK.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Immunotherapy by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Allergy Immunotherapy in the United Kingdom are Stallergenes Greer, ALK-Abelló, Allergy Therapeutics, and GlaxoSmithKline (GSK). Stallergenes Greer, headquartered in London, UK, specializes in allergy immunotherapy and recently acquired Allergy Therapeutics to strengthen its market position. ALK-Abelló, a Denmark-based multinational, is known for its standardized SLIT tablets and SCIT formulations, including EMA-approved products for dust mite allergies. Allergy Therapeutics plc, based in Worthing, UK, focuses on diverse vaccine portfolios and rapid-onset immunotherapy innovations. GSK, a major UK pharmaceutical company, is also a key player in allergy therapeutics with a broad product portfolio targeting allergic disorders.
These companies dominate the UK allergy immunotherapy market, which was valued at approximately $603 million in 2022 and forecast to grow steadily with a CAGR of 4.4% through 2030. They focus on both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), with innovations in recombinant allergen platforms, improved formulations, and delivery methods enhancing treatment safety and efficacy. The market competitiveness is driven by regulatory approvals, product differentiation, and extensive clinical validation, ensuring these companies maintain leadership in allergy immunotherapy within the UK.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
